Ascenion Mediates License Agreement for Novel Antibiotic against Tuberculosis

24-Mar-2009 - Germany

Ascenion announced, that it has negotiated a licensing contract providing Inverness Medical Innovations, Inc. with worldwide, exclusive rights to a novel antibiotic for the treatment of tuberculosis. Ascenion has initiated and mediated the agreement on behalf of an international consortium of patent owners including a Russian inventor, the Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute (HKI) and the Institut Pasteur.

The compound, a benzothiazinone derivate, was generated by the Russian scientist Dr Vadim Makarov and tested for antibacterial activity by Dr Ute Möllmann and her team at the HKI. Based on her multiyear experience in antibiotics research and Makarov's capabilities in organic chemistry, they gradually optimized the compound for selectivity and efficacy against Mycobacterium tuberculosis, the pathogen that causes tuberculosis. The result is a novel antibiotic candidate that selectively kills mycobateria at exceptionally low concentrations, including strains that are resistant against one or more available antibiotics. Moreover, preclinical studies performed in collaboration with the Institute Pasteur suggest a good side-effect profile and favourable pharmacodynamic properties.

"The new compound has strong potential to overcome resistance. This, together with its favourable properties and advanced stage of development, has triggered strong interest in the pharmaceutical industry," Peter Ruile, COO of Ascenion comments. "In choosing a commercialization partner, it was most important to us and to the inventors that the project would attain top priority within the partner's development portfolio. Inverness provides an ideal match because the project fits their product development strategy perfectly. We look forward to monitoring the project's progress through clinical trials and towards the market."

Original publication: Makarov V, Manina G, Mikusova K, Möllmann U et al.; "Benzothiazinones kill mycobacterium tuberculosis by blocking arabinan synthesis." Science 2009.

https://www.bionity.com/en/news/98649/ascenion-mediates-license-agreement-for-novel-antibiotic-against-tuberculosis.html